Seiichi Yokoyama
President & CEO

April 2007 marked a new milestone in our history. Under the name Asubio Pharma, we became a wholly owned subsidiary of Daiichi Sankyo Co., Ltd.
The word "Asubio" is derived from Asklepios, the god of medicine and healing in Greek mythology, and Asu-no-bio, which means "Life for the Future" in Japanese. As our name proclaims, Asubio Pharma is dedicated to healing illness and alleviating the pain of patients all over the world by providing superior pharmaceuticals and medical services, based on advanced scientific research and in strict accordance with ethics and rational economics.

Ever since we began researching and developing pharmaceuticals in 1979 as a business division of Suntory Limited, we have focused on the creation of innovative ethical drugs through chemical synthesis and other new technologies, notably in the fields of biotechnology and peptide chemistry. Achievements to date include the in-house development of Sunrythm^®, HANP^® and three other new drugs on the market.

Asubio Pharma will carry out its mission with the spirit of "Dreams, Challenge and Creativity" it inherited from Suntory. We will maintain our focus on new drug discovery through in-house efforts while taking full advantage of the global development capabilities and technology platforms of the Daiichi Sankyo Group. At the same time, we will actively promote alliances with pharmaceutical companies, research institutes, venture companies and universities. We continue our commitment to enhancing the quality of life around the world by creating safe and effective drugs that fill unmet therapeutic needs.

Seiichi Yokoyama
President & CEO